Could cause temporary or reversible harm; serious harm is unlikely.
cGMP deviations.
| Distributed by / for | Wells Pharma of Houston LLC |
| NDC | 73702-202-03 |
| Full product label | fentaNYL Citrate injectable Solution in 0.9% Sodium Chloride, Narcotic, (2500 mcg/ 250 mL) (10 mcg per mL), 250 mL bag, wells pharma of Houston, NDC 73702-202-03. |
| Recalling firm | Wells Pharma of Houston LLC |
| Distribution | U.S. Nationwide. |
| Quantity | 2940 IV Bags |
| Recall initiated | 2026-04-01 |
| Report date | 2026-05-06 |
| Recall completed | — |
| Recall number | D-0504-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Houston TX United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗